Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7475 pages
Showing 901 - 950European OnCovid Registry Analysis of COVID-19 Sequelae During Omicron Phase vs Earlier Phases in Patients With Cancer
In an analysis from the European OnCovid registry reported in The Lancet Oncology, Alessio Cortellini, PhD, and colleagues found that rates of COVID-19 sequelae among patients with cancer were lower during the omicron phase of the pandemic vs the alpha-delta and prevaccination phases, consistent...
Impact of Tai Ji Quan or Strength Training vs Stretching in Preventing Falls in Postmenopausal Women Who Received Chemotherapy for Cancer
In the GET FIT study reported in the Journal of Clinical Oncology, Winters-Stone et al found no significant difference in incidence of falls with programs of tai ji quan (also known as tai chi) or strength training vs a stretching control group among postmenopausal women who had received...
Trends in Active Surveillance for Management of Low-Risk Prostate Cancer in the United States
In an analysis reported in JAMA Network Open, Cooperberg et al found that the use of active surveillance (AS) for low-risk prostate cancer in U.S. patients has more than doubled in recent years but remains suboptimal and exhibits wide variations at the urology practice and individual practitioner...
Nirogacestat May Benefit Patients With Desmoid Tumors
As reported in The New England Journal of Medicine by Gounder et al, the phase III DeFi trial has shown significant improvement in progression-free survival with the investigational oral γ-secretase inhibitor nirogacestat vs placebo in patients with desmoid tumors. As noted by the investigators,...
Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer With High FRα Expression
As reported in the Journal of Clinical Oncology by Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, and colleagues, the phase II SORAYA study has shown activity of mirvetuximab soravtansine-gynx, an antibody-drug conjugate targeting folate receptor α (FRα), in women with...
Tucatinib With Trastuzumab in Previously Treated RAS Wild-Type HER2-Positive Advanced Colorectal Cancer
On January 19, 2023, tucatinib was grated accelerated approval for use in combination with trastuzumab for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.1 Supporting Efficacy...
Omission of Radiotherapy in Children and Adolescents With Early-Stage Classical Hodgkin Lymphoma With Adequate Response to OEPA Chemotherapy
As reported in The Lancet Oncology by Mauz-Körholz et al, children and adolescents with early-stage classical Hodgkin lymphoma enrolled in the EuroNet-PHL-C1 study who had an adequate response to an OEPA chemotherapy regimen (vincristine, etoposide, prednisone, and doxorubicin) and did not receive...
Long-Term Results of European Pediatric Soft-Tissue Sarcoma Study in Nonmetastatic Rhabdomyosarcoma
In an analysis reported in the Journal of Clinical Oncology, Gianni Bisogno, MD, PhD, and colleagues detailed 5-year outcomes among children and adolescents with nonmetastatic rhabdomyosarcoma in the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. Study Details The RMS2005 study...
Sacituzumab Govitecan-hziy in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
On February 3, 2023, sacituzumab govitecan-hziy was approved for unresectable locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization–negative) breast cancer who have received endocrine-based therapy and at...
Nicotinamide for Chemoprevention of Skin Cancer in Solid Organ Transplant Recipients
In an Australian phase III trial (ONTRANS) reported in The New England Journal of Medicine, Allen et al found that 1 year of treatment with nicotinamide (vitamin B3) vs placebo did not reduce the risk of keratinocyte cancers or actinic keratoses in immunosuppressed solid organ transplant...
Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On January 27, 2023, elacestrant was approved by the U.S. Food and Drug Administration (FDA) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine ...
Study Finds Cancer Screening in the United States Lagged During the Second Year of the COVID-19 Pandemic
In a study reported in the Journal of Clinical Oncology, Star et al found that cancer screening remained below prepandemic levels in the United States during the second year of the COVID-19 pandemic. Study Details Data on past-year receipt of age-eligible screening for breast cancer (women aged 50...
Nivolumab Followed by Nivolumab/Ipilimumab Boosting in Nonresponders Among Previously Treated Patients With Advanced Urothelial Carcinoma
In a German-Austrian phase II study (TITAN-TCC) reported in The Lancet Oncology, Grimm et al found that a strategy of nivolumab monotherapy followed by immunotherapeutic boosting including high-dose ipilimumab in nivolumab nonresponders showed activity in patients with unresectable or metastatic...
Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment and Overall Survival in Older Patients With Cancer
In a study reported in the Journal of Clinical Oncology, Eng et al found that exposure to antibiotics within 1 year of starting immune checkpoint inhibitor therapy was associated with poorer survival among patients with cancer who were aged 65 years and older. Study Details The population-based...
Adjuvant Paclitaxel and Trastuzumab in Node-Negative, HER2-Positive Breast Cancer: Long-Term Follow-up
In an analysis reported in The Lancet Oncology, Sara M. Tolaney, MD, MPH, and colleagues described 10-year survival outcomes from the phase II APT trial assessing adjuvant paclitaxel/trastuzumab in patients with node-negative, HER2-positive breast cancer. Study Details The U.S. multicenter trial...
PSA Level at Time of Salvage Radiation Therapy After Radical Prostatectomy and Risk of All-Cause Mortality
In a study reported in the Journal of Clinical Oncology, Derya Tilki, MD, and colleagues identified a prostate-specific antigen (PSA) level cutpoint, above which initiation of salvage radiation therapy after radical prostatectomy was associated with an increased risk of all-cause mortality in...
First-Line Lenvatinib/Pembrolizumab vs Sunitinib in Advanced Renal Cell Carcinoma: Extended Follow-up of the CLEAR Trial
As reported in The Lancet Oncology by Toni K. Choueiri, MD, and colleagues, extended follow-up of the phase III CLEAR trial has shown maintained progression-free and overall survival benefits with first-line lenvatinib plus pembrolizumab vs sunitinib in patients with advanced clear cell renal cell...
Dinutuximab Beta and Interleukin-2 After Haploidentical Stem Cell Transplantation in Patients With Relapsed Neuroblastoma
In a phase I/II trial reported in the Journal of Clinical Oncology, Flaadt et al found that treatment with the anti-GD2 antibody dinutuximab beta plus low-dose interleukin-2 (IL-2) following haploidentical stem cell transplantation (haplo-SCT) is feasible in patients with relapsed high-risk...
Neoadjuvant Plus Adjuvant vs Adjuvant Pembrolizumab in Advanced Melanoma
In the phase II SWOG Cancer Research Network S1801 trial reported in The New England Journal of Medicine, Sapna P. Patel, MD, and colleagues found that neoadjuvant plus adjuvant pembrolizumab significantly improved event-free survival vs adjuvant pembrolizumab alone in patients with stage IIIB to...
Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma: 5-Year Results of the ZUMA-1 Trial
As reported in the journal Blood by Sattva S. Neelapu, MD, and colleagues, 5-year outcomes from the the phase II ZUMA-1 trial showed that axicabtagene ciloleucel was associated with maintained response in one-third of patients with refractory large B-cell lymphoma. The estimated 5-year overall...
First-Line Pembrolizumab in Older Patients With dMMR Metastatic Colorectal Cancer
In a retrospective cohort study reported in JAMA Network Open, Saberzadeh-Ardestani et al found that first-line pembrolizumab was associated with clinically significant prolongation of survival outcomes in mostly older patients with mismatch repair–deficient (dMMR) metastatic colorectal cancer....
Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer
In the phase II CALYPSO study reported in the Journal of Clinical Oncology, Suárez et al found that the combination of the MET inhibitor savolitinib and the PD-L1 inhibitor durvalumab did not reach the confirmed response rate endpoint in patients with metastatic papillary renal cancer but showed...
Surgeon-Anesthesiologist Familiarity and Short-Term Outcomes in Complex Gastrointestinal Cancer Surgery
In a Canadian population–based retrospective cohort study reported in JAMA Surgery, Hallet et al found that increased familiarity among surgeon-anesthesiologist dyads—measured by annual number of procedures performed together—was associated with better short-term postoperative outcomes in complex...
Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Patients With Cancer
In an analysis reported in JACC: CardioOncology, Zhu et al found that in the United States, Black patients with cancer were at increased risk of all-cause mortality and cardiovascular (CVD) mortality compared with White patients, and that White patients were at increased risk of both outcomes...
Prognosis of HER2-Low vs HER2-Negative Breast Cancer
In an analysis of National Cancer Database data reported in JAMA Oncology, Peiffer et al found “minimal prognostic differences” between HER2-low vs HER2-negative breast cancer, with the findings not supporting classification of HER2-low disease as a distinct disease subtype. Study Details The...
Can Long Noncoding RNA Expression Help Predict Outcomes in Pediatric Patients With AML?
In a study reported in the Journal of Clinical Oncology, Farrar et al developed a long noncoding RNA (lncRNA) transcription scoring system that distinguished survival outcomes in pediatric patients with acute myeloid leukemia (AML). As stated by the investigators, “Risk classification in pediatric...
Association of Baseline and Subsequent Cardiovascular Health Metrics With Risk for Incident Cancers
In an analysis from the French GAZEL study reported in JACC: CardioOncology, Van Sloten et al found that better cardiovascular health scores at baseline and improvement in scores over 7 years were associated with a reduced risk of incident cancers. As stated by the investigators, “The commonality...
Addition of Pembrolizumab to Pemetrexed/Platinum in the First-Line Treatment of Metastatic Nonsquamous NSCLC: 5-Year Outcomes in the KEYNOTE-189 Study
As reported in the Journal of Clinical Oncology by Marina C. Garassino, MD, and colleagues, 5-year follow-up in the phase III KEYNOTE-189 trial has shown maintained progression-free and overall survival benefits with the addition of pembrolizumab to pemetrexed and platinum chemotherapy in the...
Prediction Models for Kidney Failure in Long-Term Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Wu et al developed models for predicting kidney failure among 5-year survivors of childhood cancer. Study Details In the study, predictive models were developed using data from 25,483 survivors from the Childhood Cancer Survivor Study (CCSS)...
Survival in Patients With Brain Metastases: Limited or Stable Extracranial Disease
In a systematic review and meta-analysis reported in JAMA Network Open, Li et al found that patients with intracranial metastatic disease in the context of limited or stable extracranial disease (IMD-SE) secondary to any primary cancer had improved overall survival vs those with intracranial...
De-escalated Neoadjuvant T-DM1 With or Without ET vs Trastuzumab With ET in Hormone Receptor–Positive/HER2-Positive Early Breast Cancer
As reported in the Journal of Clinical Oncology by Nadia Harbeck, MD, PhD, and colleagues, 5-year follow-up from the phase II WSG-ADAPT-TP trial indicated that pathologic complete response (pCR) was associated with better outcomes irrespective of receipt of adjuvant chemotherapy among patients with ...
Prevalence of High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Patients With BRCA1/2 Pathogenic Variants
In a Dutch study reported in the Journal of Clinical Oncology, Stroot et al identified the prevalence of high-grade serous carcinoma at risk-reducing salpingo-oophorectomy in asymptomatic BRCA1/2 pathogenic variant carriers. Study Details The study included asymptomatic BRCA1/2 pathogenic variant...
Darolutamide Plus ADT and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: Outcomes by Disease Volume and Risk Status in the ARASENS Trial
In an analysis from the phase III ARASENS trial reported in the Journal of Clinical Oncology, Maha Hussain, MD, FACP, FASCO, and colleagues found that the addition of darolutamide to androgen-deprivation therapy (ADT) and docetaxel significantly improved overall survival in subgroups of patients...
Mediterranean Diet and Immune Checkpoint Blockade Outcomes in Advanced Melanoma
In the PRIMM study reported in JAMA Oncology, Bolte et al found that consumption of a Mediterranean diet was associated with a high probability of objective response and 12-month progression-free survival among patients receiving immune checkpoint blockade treatment for advanced melanoma. As stated ...
Association of Immune-Related Adverse Events With Overall Survival in Patients Receiving Atezolizumab-Containing Therapy for Metastatic Nonsquamous NSCLC
In a pooled analysis reported in JAMA Oncology, Mark A. Socinski, MD, and colleagues found that patients with nonsquamous non–small cell lung cancer (NSCLC) receiving atezolizumab who had grade 1 or 2 immune-related adverse events in clinical trials had improved overall survival vs those with no...
Remote Interventions to Improve Uptake of Cancer Genetic Risk Assessment in Patients With Ovarian Cancer or High-Risk Breast Cancer
In a study reported in the Journal of Clinical Oncology, Anita Y. Kinney, PhD, RN, and colleagues found that a phone-based tailored risk counseling and navigation intervention resulted in a higher proportion of patients with ovarian or high-risk breast cancers receiving cancer genetic risk...
Residual Nonretroperitoneal Disease After Chemotherapy for Nonseminomatous Germ Cell Tumors
In a single-institution study reported in the Journal of Clinical Oncology, King et al identified the prevalence of teratoma and active germ cell tumor in patients with residual nonretroperitoneal disease following chemotherapy for advanced nonseminomatous germ cell tumors. As stated by the...
Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
On January 19, 2023, the kinase inhibitor zanubrutinib was approved for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 Supporting Efficacy Data Approval was based on findings in the SEQUOIA trial (ClinicalTrials.gov identifier NCT03336333) in patients with...
KarMMa-3: Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Rodriguez‑Otero et al, an interim analysis of the phase III KarMMa-3 trial showed superior progression-free survival with the B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel) vs...
Adjuvant Nivolumab/Ipilimumab vs Placebo in Localized Renal Cell Carcinoma
As reported in The Lancet by Robert J. Motzer, MD, and colleagues, part A of the phase III CheckMate 914 trial has shown no improvement in disease-free survival with adjuvant nivolumab/ipilimumab vs placebo in resected localized clear cell renal cell carcinoma. Part B of the trial is evaluating...
Discordance of p16 and HPV DNA/RNA Status: Prognostic Implication in Squamous Cell Oropharyngeal Carcinoma
In a study reported in The Lancet Oncology, Hisham Mehanna, FRCS, and colleagues found that concordance and discordance of p16 immunohistochemistry and human papillomavirus (HPV) DNA/RNA testing were associated with different outcomes among patients with squamous cell oropharyngeal carcinoma....
PRIME II Trial: Breast-Conserving Surgery With or Without Radiotherapy in Early Breast Cancer
As reported in The New England Journal of Medicine by Ian H. Kunkler, MB, BChir, MA, FRCR, and colleagues, the phase III PRIME II trial has shown a higher risk of local recurrence with the omission of adjuvant radiotherapy after breast-conserving surgery in patients aged ≥ 65 years with hormone...
Addition of Bortezomib to First-Line Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia
As reported in the Journal of Clinical Oncology by Buske et al, the European Consortium for Waldenström’s Macroglobulinemia (ECWM)-1 study has shown a numeric benefit in progression-free survival with the addition of bortezomib to dexamethasone, rituximab, and cyclophosphamide (DRC; B-DRC) in the...
First-Line Tyrosine Kinase Inhibitor Therapy for Advanced Clear Cell Renal Cell Carcinoma: Temporary Treatment Cessation vs Continuation
As reported in The Lancet Oncology by Brown et al, the phase II/III STAR trial showed that noninferiority in overall survival and quality-adjusted life-years (QALYs) could not be concluded for temporary treatment cessation vs continuous treatment with first-line tyrosine kinase inhibitor therapy in ...
Addition of Avelumab to Carboplatin/Paclitaxel in First-Line Treatment of Advanced or Recurrent Endometrial Cancer
As reported in The Lancet Oncology by Sandro Pignata, MD, and colleagues, the Italian phase II MITO END-3 trial showed no progression-free survival benefit with the addition of first-line avelumab to carboplatin/paclitaxel in patients with advanced or recurrent endometrial cancer. A trend toward...
Nivolumab and Relatlimab in Patients With Advanced Melanoma Progressing on Anti–PD-1/PD-L1 Therapy
As reported in the Journal of Clinical Oncology by Paolo Antonio Ascierto, MD, and colleagues, the phase I/IIa RELATIVITY-020 trial part D has shown evidence of activity of the combination of nivolumab and relatlimab in patients with advanced melanoma progressing on anti–PD-1/PD-L1 therapy. Study...
TRITON3: Rucaparib vs Physician’s Choice of Single-Agent Therapy in Metastatic Castration-Resistant Prostate Cancer With BRCA or ATM Alterations
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the entire population of patients with metastatic...
Updated Results From the ADAURA Trial: Continued Disease-Free Survival Benefit With Adjuvant Osimertinib vs Placebo in EGFR-Mutated Stage IB–IIIA NSCLC
As reported in the Journal of Clinical Oncology by Roy S. Herbst, MD, PhD, of Yale Cancer Center and Yale School of Medicine, and colleagues, updated findings in the phase III ADAURA trial showed continued disease-free survival benefit with adjuvant osimertinib vs placebo after complete resection...
Allogeneic HCT vs Consolidation Chemotherapy in Patients Aged 60 Years or Younger With Intermediate-Risk AML
In a German phase III trial reported in JAMA Oncology, Bornhäuser et al found that allogeneic hematopoietic cell transplantation (HCT) was not associated with improved overall survival vs standard consolidation chemotherapy in patients aged ≤ 60 years with cytogenetically defined intermediate-risk...
Encorafenib, Binimetinib, and Cetuximab in Previously Untreated Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
In the phase II ANCHOR CRC trial reported in the Journal of Clinical Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that the combination of encorafenib, binimetinib, and cetuximab produced an objective response in nearly half of previously untreated patients with BRAF V600E–mutant...
